CP 55,940
CP 55,940[edit | edit source]
CP 55,940 is a synthetic cannabinoid that was developed in the 1970s by the pharmaceutical company Pfizer. It is a potent agonist of the cannabinoid receptors, specifically the CB1 receptor and CB2 receptor. CP 55,940 is often used in scientific research to study the endocannabinoid system and its effects on the body.
Chemical Structure and Properties[edit | edit source]
CP 55,940 is a bicyclic compound with a complex structure that includes a cyclohexane ring and a phenol group. The chemical formula of CP 55,940 is C23H32O2, and it has a molecular weight of 340.5 g/mol. The compound is lipophilic, allowing it to easily cross the blood-brain barrier and interact with cannabinoid receptors in the central nervous system.
Mechanism of Action[edit | edit source]
CP 55,940 acts as a full agonist at both the CB1 and CB2 receptors. These receptors are part of the G protein-coupled receptor family and are primarily involved in modulating neurotransmitter release in the brain. Activation of CB1 receptors by CP 55,940 leads to a decrease in neurotransmitter release, which can result in effects such as analgesia, sedation, and appetite stimulation.
Research Applications[edit | edit source]
CP 55,940 is widely used in research to explore the physiological and pharmacological roles of the endocannabinoid system. It is often employed in studies investigating the effects of cannabinoids on pain, inflammation, and neurodegenerative diseases. Additionally, CP 55,940 is used to study the potential therapeutic applications of cannabinoids in conditions such as multiple sclerosis, epilepsy, and cancer.
Safety and Toxicity[edit | edit source]
As a research chemical, CP 55,940 is not intended for human consumption. Studies have shown that it can produce effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. However, due to its potency, CP 55,940 can also lead to more pronounced side effects, including anxiety, paranoia, and tachycardia.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
